Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
8 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Obesity / overweightHigh blood pressure
Impact GLP-1 Agonists Following Bariatric
Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar
📍 University of Missouri Hospital · Columbia, MO · Get directions →
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.
- Multiple sclerosis (MS)
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis
📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).
- Obesity / overweightHigh blood pressureCOPD (chronic lung disease)
Feasibility of Semaglutide in Advanced Lung Disease
Testing whether semaglutide can be given safely to people with advanced lung disease
📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.
- Multiple sclerosis (MS)
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Testing how ocrelizumab and GLP-1 medicines affect disability in multiple sclerosis
📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →
The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.
- Obesity / overweightHigh blood pressure
Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study
Testing how an egg-derived peptide affects health in people with obesity and high blood pressure
📍 University of Alberta · Edmonton, Alberta · Get directions →
Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides.
- Eczema / atopic dermatitis
Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population
Testing a milk-peptide cream to see if it improves childhood eczema and reduces skin bacteria
📍 Universidad Autónoma de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →
The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of glycomacropeptide is associated with a lower colonization by Staphylococcus species on the skin. The main questions that it aims to answer are: * Does glycomacropeptide reduce the signs and symptoms related to atopic dermatitis in the pediatric population?
- Obesity / overweightHigh blood pressure
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
Studying what happens to heart health and weight after stopping a weight-loss drug in people with
📍 Leadership Sinai Centre for Diabetes · Toronto, Ontario · Get directions →
Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide.
- DepressionAnxiety
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
Testing whether a brain drug affects decision-making in depression and anxiety
📍 Mclean Hospital · Belmont, MA · Get directions →
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).